Related references
Note: Only part of the references are listed.Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
Zhendong Song et al.
ACTA PHARMACEUTICA SINICA B (2021)
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Chen Liu et al.
CLINICAL CANCER RESEARCH (2021)
Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities - A comprehensive review
Rati Kailash Prasad Tripathi et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2021)
Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview
Rangan Mitra et al.
CHEMMEDCHEM (2021)
Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders
Xiangbo Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Novel PROTACs for degradation of SHP2 protein
Mengzhu Zheng et al.
BIOORGANIC CHEMISTRY (2021)
A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors
Yihui Song et al.
ACTA PHARMACEUTICA SINICA B (2021)
Therapeutic potential of targeting SHP2 in human developmental disorders and cancers
Dadong Shen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Shp2 activation in bone marrow microenvironment mediates the drug resistance of B-cell acute lymphoblastic leukemia through enhancing the role of VCAM-1/VLA-4
Kunlin Yu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Targeting SHP2 as a promising strategy for cancer immunotherapy
Qianqian Liu et al.
PHARMACOLOGICAL RESEARCH (2020)
Molecular mechanism of SHP2 activation by PD-1 stimulation
M. Marasco et al.
SCIENCE ADVANCES (2020)
Immune checkpoint signaling and cancer immunotherapy
Xing He et al.
CELL RESEARCH (2020)
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Mingliang Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Xinrui Yuan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds
Wenjie Guo et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2020)
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
Yuting Sun et al.
CANCER RESEARCH (2020)
Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation
Guangya Zhu et al.
CELL (2020)
Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders
Kai Tang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
Matthew J. LaMarche et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors
Jeffrey T. Bagdanoff et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors
Patrick Sarver et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Genetic abnormalities and pathophysiology of MDS
Naoko Hosono
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer
Lingjuan He et al.
ONCOTARGETS AND THERAPY (2019)
Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
Javier Celis-Gutierrez et al.
CELL REPORTS (2019)
SHP2 inhibitor specifically suppresses the sternness of KRAS-mutant non-small cell lung cancer cells
Lei Jiang et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2019)
An allosteric inhibitor of SHP2 effectively targets PDGFRα-driven glioblastoma
Bakhos A. Tannous et al.
NEURO-ONCOLOGY (2019)
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
Mingxia Zhao et al.
ACTA PHARMACEUTICA SINICA B (2019)
Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway
Fan Yang et al.
ONCOTARGETS AND THERAPY (2019)
Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer
Ming-Jenn Chen et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
Katharina Sies et al.
HEMASPHERE (2019)
Responses to Cytokines and Interferons that Depend upon JAKs and STATs
George R. Stark et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Dual Allosteric Inhibition of SHP2 Phosphatase
Michelle Fodor et al.
ACS CHEMICAL BIOLOGY (2018)
Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET
Jacey J. Liu et al.
JOURNAL OF HEPATOLOGY (2018)
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Dietrich A. Ruess et al.
NATURE MEDICINE (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Leila Dardaei et al.
NATURE MEDICINE (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
The tyrosine phosphatase SHP2 controls TGF beta-induced STAT3 signaling to regulate fibroblast activation and fibrosis
Ariella Zehender et al.
NATURE COMMUNICATIONS (2018)
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
Ricardo A. P. Padua et al.
NATURE COMMUNICATIONS (2018)
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
Jonathan R. LaRochelle et al.
NATURE COMMUNICATIONS (2018)
Shipping Out MeK Inhibitor Resistance with sHP2 Inhibitors
Pedro Torres-Ayuso et al.
CANCER DISCOVERY (2018)
The Allosteric Site on SHP2's Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules
Brennan Marsh-Armstrong et al.
ACS OMEGA (2018)
TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy
Xin-guang Liu et al.
IMMUNOLOGICAL INVESTIGATIONS (2017)
Shp2 Promotes Liver Cancer Stem Cell Expansion by Augmenting β-Catenin Signaling and Predicts Chemotherapeutic Response of Patients
Daimin Xiang et al.
HEPATOLOGY (2017)
The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy
Fatima Ardito et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3
Chen Qi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment
Jingjing Xie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Phosphorylation: Implications in Cancer
Vishakha Singh et al.
PROTEIN JOURNAL (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells
Yu-Jing Sun et al.
ONCOTARGET (2017)
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells
Zhuqing Liu et al.
ONCOTARGET (2017)
Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798
Xuemei Yang et al.
ONCOTARGET (2017)
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma (vol 55, pg 1041, 2011)
Wei-Tien Tai et al.
JOURNAL OF HEPATOLOGY (2017)
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2
Jonathan R. LaRochelle et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
Jorge Garcia Fortanet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
B. M. Richine et al.
LEUKEMIA (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
An increase in galectin-3 causes cellular unresponsiveness to IFN-γ-induced signal transduction and growth inhibition in gastric cancer cells
Po-Chun Tseng et al.
ONCOTARGET (2016)
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2
Susanne B. Breitkopf et al.
SCIENTIFIC REPORTS (2016)
Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2
Cynthia M. Chio et al.
BIOCHEMISTRY (2015)
SHP2 sails from physiology to pathology
Mylene Tajan et al.
EUROPEAN JOURNAL OF MEDICAL GENETICS (2015)
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients
Tao Han et al.
JOURNAL OF HEPATOLOGY (2015)
Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Severa Bunda et al.
NATURE COMMUNICATIONS (2015)
Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development
Rong Deng et al.
ONCOTARGET (2015)
Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations
Zhi-Hong Yu et al.
BIOCHEMISTRY (2014)
Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells
K. S. Siveen et al.
BRITISH JOURNAL OF CANCER (2014)
The second-sphere residue T263 is important for the function and catalytic activity of PTP1B via interaction with the WPD-loop
Peng Xiao et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer
Jia Gu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)
Wei Qiu et al.
BMC STRUCTURAL BIOLOGY (2014)
Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma
Jie Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities
Wiljan J. A. J. Hendriks et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma
L. B. Dong et al.
GENETICS AND MOLECULAR RESEARCH (2013)
Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 Mutations
Zhi-Hong Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-β production
Fei Meng et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2013)
The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo
S. C. Nabinger et al.
LEUKEMIA (2013)
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes
Helena Tassidis et al.
TUMOR BIOLOGY (2013)
Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2
Hla Win-Piazza et al.
CANCER LETTERS (2012)
Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver
Ma Eugenia Diaz et al.
CELLULAR SIGNALLING (2012)
Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer
Po-Chun Tseng et al.
IMMUNOBIOLOGY (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Expression and Clinical Significance of SHP2 in Gastric Cancer
S. Dong et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop
Nicola Aceto et al.
NATURE MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells
Liang Li et al.
BLOOD (2011)
Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Emilie A. Bard-Chapeau et al.
CANCER CELL (2011)
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans
Kun-Wei Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Helicobacter pylori CagA Phosphorylation Status Determines the gp130-activated SHP2/ERK and JAK/STAT Signal Transduction Pathways in Gastric Epithelial Cells
In Ohk Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3β Signaling
Thomas Edouard et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Cytokine signalling via gp130 in gastric cancer
M. Howlett et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2009)
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis
Gordon Chan et al.
BLOOD (2009)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
Constitutively Active SHP2 Cooperates with HoxA10 Overexpression to Induce Acute Myeloid Leukemia
Hao Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Gordon Chan et al.
CANCER AND METASTASIS REVIEWS (2008)
The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
Marie Dance et al.
CELLULAR SIGNALLING (2008)
Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes
Simone Martinelli et al.
HUMAN MOLECULAR GENETICS (2008)
Inhibition of IFN-γ-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2
Michel Baron et al.
JOURNAL OF IMMUNOLOGY (2008)
Mediating ERK1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome
Tomoki Nakamura et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The tyrosine phosphatase SHP-2 regulates differentiation and apoptosis of individual T lymphocytes
Holger Hoff et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Rebecca J. Chan et al.
BLOOD (2007)
An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival
WT Yang et al.
DEVELOPMENTAL CELL (2006)
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling
P Uhlén et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Live-cell imaging of endogenous Ras-GTP illustrates predominant Ras activation at the plasma membrane
M Augsten et al.
EMBO REPORTS (2006)
Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation
R Pai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor
RJ Chan et al.
BLOOD (2005)
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
MG Mohi et al.
CANCER CELL (2005)
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
ML Loh et al.
BLOOD (2004)
Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor
Y Ren et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Shp2 regulates Src family kinase activity and Ras/Erk activation by controlling Csk recruitment
SQ Zhang et al.
MOLECULAR CELL (2004)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
M Bentires-Alj et al.
CANCER RESEARCH (2004)
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia
M Tartaglia et al.
BLOOD (2004)
SHP-2 positively regulates myogenesis by coupling to the rho GTPase signaling pathway
MI Kontaridis et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Structural analysis of autoinhibition in the Ras activator son of sevenless
H Sondermann et al.
CELL (2004)
Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation
A Fragale et al.
HUMAN MUTATION (2004)
SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor
S Ali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
YM Agazie et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes
A Sarkozy et al.
JOURNAL OF MEDICAL GENETICS (2003)
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
M Tartaglia et al.
NATURE GENETICS (2003)
Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutanesous syndrome
L Musante et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2003)
Regulation of JAK-STAT signalling in the immune system
K Shuai et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Anticancer activity of sodium stibogluconate in synergy with IFNs
TL Yi et al.
JOURNAL OF IMMUNOLOGY (2002)
Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
H Hanafusa et al.
NATURE CELL BIOLOGY (2002)
mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins
D Tefft et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2002)
Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2
SQ Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors
CJ Wu et al.
ONCOGENE (2001)
Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines
MK Pathak et al.
JOURNAL OF IMMUNOLOGY (2001)
Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase
BD Cuevas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Combinatorial control of the specificity of protein tyrosine phosphatases
NK Tonks et al.
CURRENT OPINION IN CELL BIOLOGY (2001)
Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor
M You et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
The SHP-2 tyrosine phosphatase: Signaling mechanisms and biological functions
CK Qu
CELL RESEARCH (2000)
A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling
GA Rodrigues et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Dissection of signaling cascades through gp130 in vivo: Reciprocal roles for STAT3-and SHP2-mediated signals in immune responses
T Ohtani et al.
IMMUNITY (2000)
Share Paper
